Answer
Males and females of reproductive potential receiving LysaKare with lutetium-177 oxodotreotide should use effective contraception during lutetium-177 oxodotreotide treatment and consult section 4.6 of its SmPC for further treatment-specific guidance.
Sources for this answer
- LysaKare 25 g/25 g solution for infusionNovartis Pharmaceuticals UK Ltd · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 6Document updated
Sources checked